72 Chapter 4 Table 4. Overview of studies reporting prognosis Cardiac Mortality MACE Study Total cohort (n) Total ANOCA Cohort n (%) ANOCA with ES n (%) ANOCA without ES n (%) Total Cohort n (%) ANOCA with ES n (%) ANOCA without ES n (%) Aziz (2017)* (n=847) 3 (0.5) 2 (0.8) 1 (0.3) NR NR NR Bory (1996) (n=277) 10 (3.6) 10 (3.6) NA NR NR NR Choi (2019) (n=5890) NR NR NR NR NR NR Figueras (2013) (n=657) 25 (3.8) 15 (5.5) 10 (2.6) NR NR NR Ford (2019) * (n=151) NR NR NR 17 (11.3) 17 (11.3) NA Lee (2017) (n=986) 13 (1.3) 13 (1.3) NA 191 (19.4) 191 (19.4) NA Nishimiya (2021) (n=329) 0 (0) 0 (0) 0 (0) 17 (5.2) 17 (6.9) 0 (0) Sato (2013) (n=1877) NR 3 (0.3) NR NR 43 (5.9) NR Schoenenberger (2016) (n=718) 4 (0.6) 4 (2.8) 0 (0) NR NR NR Sheikh (2018) (n=49) NR NR NR NR NR NR Suda (2019) (n=187) 1 (0.5) NR NR 10 (5.4) NR NR Total 56 (1.5) 47 (1.6) 11 (0.9) 235 (14.4) 268 (12.0) 0 (0) Total comparative studies 32 (1.4) 21 (2.3) 11 (0.9) 17 (5.4) 17 (6.9) 0 (0) Follow-up data are presented in mean ± SD or median (interquartile range). * Data retrieved from other studies from the same study cohort; ^ incidence reported at first 11.7 years; # range instead of IQR; ANOCA, angina with no obstructive coronary arteries; CAG, coronary angiography; CAS, coronary artery spasm; ES, epicardial spasm; HF, heart failure; ICFT, invasive coronary function test; IMR, index of microcirculatory resistance; MACE, major adverse cardiac events; MI, myocardial infarction; MS, microvascular spasm; NR, Not reported; SAQ, seattle angina questionnaire; QoL, quality of life.
RkJQdWJsaXNoZXIy MTk4NDMw